44,310 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. acquired a new stake in Atyr PHARMA INC (NASDAQ:ATYR) in the 4th quarter, Holdings Channel reports. The fund acquired 44,310 shares of the company’s stock, valued at approximately $160,000.

Several other large investors also recently bought and sold shares of ATYR. Alterna Wealth Management Inc. acquired a new stake in shares of Atyr PHARMA during the fourth quarter worth about $36,000. Victory Capital Management Inc. purchased a new position in Atyr PHARMA during the 4th quarter worth approximately $37,000. Raymond James Financial Inc. acquired a new position in Atyr PHARMA during the fourth quarter worth approximately $39,000. XTX Topco Ltd purchased a new stake in Atyr PHARMA in the fourth quarter valued at approximately $40,000. Finally, Boothbay Fund Management LLC purchased a new stake in Atyr PHARMA in the fourth quarter valued at approximately $53,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Atyr PHARMA Price Performance

Atyr PHARMA stock opened at $3.27 on Monday. Atyr PHARMA INC has a 12 month low of $1.42 and a 12 month high of $4.66. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The business has a 50 day simple moving average of $3.27 and a 200-day simple moving average of $3.40. The stock has a market capitalization of $291.04 million, a PE ratio of -3.48 and a beta of 0.79.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.02. Equities analysts predict that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Analyst Ratings Changes

ATYR has been the topic of a number of research reports. Leerink Partnrs upgraded shares of Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a research report on Friday, March 14th. Finally, Leerink Partners assumed coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.